Business Wire

CA-TELESIGN

22.10.2019 22:33:38 CEST | Business Wire | Press release

Share
TeleSign Expands Global Services through Partnership with Proximus

TeleSign , a leader in authentication and communication services, a wholly-owned subsidiary of BICS, today announced a new partnership with Proximus , the largest telecommunications company in Belgium. This partnership will provide TeleSign’s fraud risk product portfolio to provide regional and international companies with a presence in Belgium.

As the mobile identity ecosystem continues to rapidly evolve globally, it is more important than ever that businesses ensure the strongest authentication and verification measures to secure end-user accounts and prevent fraud, especially in the financial sector. According to PwC , almost two-thirds (65 percent) of companies in Belgium experienced economic crime in the last two years, compared to under half (49 percent) globally. Fraud such as account take over (ATO) through SIM swap and porting attacks can be significantly expensive to both end users and businesses. With the strength of Proximus’ insights and TeleSign’s expertise, this partnership will aid businesses in complying with the new EU Payment Services Directive, PSD2 and its two core use cases – Know Your Customer (KYC) and Strong Customer Authentication (SCA) .

This new partnership with Proximus highlights the increasing importance of Mobile Identity and the key role played by Mobile Operators in digital transformation. It represents a new opportunity to Mobile Operators worldwide to participate in a Global Mobile Identity ecosystem and improve the security of their end users online.

“TeleSign helps its customers globally to protect and prevent fraudulent activity for the end user and businesses,” said Pierre Demarche, VP of Products at TeleSign. “Telesign has existing partnerships with other Mobile Operators in multiple geographies, and keeps expanding its partnership with Mobile Operators worldwide, so we have a deep understanding of how Mobile Identity can be leveraged to provide end-to-end security experience. This protection not only works to prevent costly fraud, but also enhances the user experience.”

“As the leading telecommunications company in Belgium, quality of data and security services to our customers is top of mind, and so is being able to develop services that will protect our customers from fraudulent activity,” said Jeroen Degadt, Director Carrier and Wholesale at Proximus. “Partnering with TeleSign, a global neutral aggregator, was the clear choice. With access to TeleSign’s fraud risk product portfolio, we will be able to provide increased security and assurance for our customers across the country.”

TeleSign is a trusted partner to 21 of the top 25 global websites and mobile applications, enabling them to securely and effectively communicate with billions of end-user accounts. TeleSign offers telecommunications companies like Proximus the ability to secure their customer base and protect users from fraud and identity theft.

For more information about how TeleSign can support mobile operators, please visit https://info.telesign.com/Suppliers.html .

About TeleSign

TeleSign connects and protects online experiences with sophisticated customer identity and engagement solutions. Through APIs that deliver user verification, data insights, and communications we solve today’s unique customer challenges by bridging your business to the complex world of global telecommunications. TeleSign is a subsidiary of BICS, Brussels. BICS is a leading international communications enabler, one of the key global voice carriers and the leading provider of mobile data services worldwide with Proximus as its majority shareholder.

Learn more at www.telesign.com and follow us on Twitter at @TeleSign .

About Proximus

The Proximus Group is a telecommunication and ICT company operating in the Belgian and international markets, serving residential customers, businesses, and public institutions. Proximus aims to open up a world of digital opportunities so that people can live better and work smarter. The company is at the heart of the digital revolution, delivering communication and entertainment experiences for residential consumers and enabling digital transformation for enterprises. Through its best-quality integrated fixed and mobile networks, Proximus provides access anywhere and anytime to digital services and easy-to-use solutions, and is a gateway to multimedia content. Proximus is a pioneer in ICT innovation, with integrated solutions that have a positive impact on society and the environment, based on Internet of Things (IoT), Data analytics, cloudification, and security. With 13,385 employees, all striving to offer customers a superior experience, the Group realized an underlying Group revenue of EUR 5,804 million end-2018.

Proximus (Euronext Brussels: PROX) is also active in Luxembourg through its affiliate Proximus Luxembourg and in the Netherlands through Telindus Netherlands. BICS is a leading international communications enabler, one of the key global voice carriers, and the leading provider of mobile data services worldwide.

For more information, visit www.proximus.com and www.proximus.be .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye